1St George Hospital, Kogarah, Australia, 2St Vincent’s Hospital, Sydney, Australia, 3Tamworth Rural Referral Hospital, Tamworth, Australia

Background: Rituximab, a monoclonal anti-CD20 antibody is currently the third-line therapy of frequently relapsing or resistant minimal change disease. Recent pediatric case series has proposed the use of a novel humanized anti-CD20 antibody ofatumumab, reporting superior efficacy due to its ability to bind a membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab.
Case report: We describe a case of a 23-year-old male with biopsy-proven relapsing steroid-resistant minimal change disease. He has previously failed steroid and calcineurin inhibitor therapy, requiring rituximab therapy to sustain a 2-year period of remission prior to this relapse.Patient received a treatment protocol of six weekly infusions of ofatumumab (300mg for 1st week, then 2000mg weekly for 5 weeks) with a standard premedication regime. Our patient was followed up weekly in the infusion clinic with serum albumin, serum creatinine, urine albumin:creatinine ratio and body weight observed at T=0 weeks, T=3 weeks and T=6 weeks.A significant reduction in albuminuria was achieved (spot urine albumin reduced from 2190mg/L to 81mg/L, urine albumin/creatinine ratio 267.1mg/mmol to 7.4mg/mmol), with an improvement in serum albumin from 8g/L to 25g/L and improvement in clinical fluid status (89kg to 65kg) by the end of 6 weeks. His serum creatinine level improved from 166mmol/l to 68mmol/l. Our patient currently remain in remission. Ofatumumab was well tolerated throughout the 6 weeks, with the exception of one mild infusion related side effect noted on induction.
Conclusions: Ofatumumab is an effective alternative to rituximab in managing steroid/calcineurin resistant nephrotic syndrome and may confer long-term disease remission benefit over rituximab.

Jolene (Zhuo Lin) Ng is a current Basic Physician Trainee at the St George – Sutherland Basic Physician Trainee Network in New South Wales.


The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd